Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

In8Bio Inc (INAB)

In8Bio Inc (INAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,271
  • Shares Outstanding, K 31,991
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,010 K
  • 60-Month Beta 0.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.27
Trade INAB with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.17
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.18
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +43.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9164 +11.31%
on 04/12/24
1.2199 -16.39%
on 04/11/24
-0.0800 (-7.27%)
since 04/02/24
3-Month
0.9164 +11.31%
on 04/12/24
1.4500 -29.66%
on 03/08/24
-0.2900 (-22.14%)
since 02/02/24
52-Week
0.6500 +56.92%
on 11/22/23
3.4800 -70.69%
on 05/19/23
-1.1000 (-51.89%)
since 05/02/23

Most Recent Stories

More News
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June

/PRNewswire/ -- USA News Group - With this year's Annual Meeting of the American Society of Clinical Oncology (ASCO 2023) less than 30 days away, there's...

ONC.TO : 1.59 (+3.25%)
ONCY : 1.1700 (+4.46%)
JAZZ : 109.29 (-0.92%)
GERN : 3.95 (-3.19%)
INAB : 1.0200 (-1.92%)
VCYT : 20.19 (+0.30%)
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END

ONCY : 1.1700 (+4.46%)
ONC.TO : 1.59 (+3.25%)
JAZZ : 109.29 (-0.92%)
GERN : 3.95 (-3.19%)
INAB : 1.0200 (-1.92%)
VCYT : 20.19 (+0.30%)
Significant Oncology Results Set to be Delivered as Oral Presentations at ASCO 2023

USA News Group – With this year’s Annual Meeting of the American Society of Clinical Oncology (ASCO 2023) less than 30 days away, there’s plenty of anticipation for updates on some of the biggest...

ONCY : 1.1700 (+4.46%)
ONC.TO : 1.59 (+3.25%)
JAZZ : 109.29 (-0.92%)
GERN : 3.95 (-3.19%)
INAB : 1.0200 (-1.92%)
VCYT : 20.19 (+0.30%)
IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients

All three patients from the first cohort of high-risk relapsed acute-myeloid leukemia (AML) patients dosed to-date with INB-100 remain alive and...

INAB : 1.0200 (-1.92%)
Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform

European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural...

INAB : 1.0200 (-1.92%)
IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development

NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and...

INAB : 1.0200 (-1.92%)
IN8bio to Present at July Investor and Scientific Conferences

NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and...

INAB : 1.0200 (-1.92%)
IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022

100% of dosed patients have exceeded both median and expected progression free survival (PFS). Two patients, to date, having exceeded their expected...

INAB : 1.0200 (-1.92%)
IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

Phase 1 clinical trial of INB-100 in leukemia patients and INB-200 in newly diagnosed glioblastoma multiforme (GBM) patients continue to generate...

INAB : 1.0200 (-1.92%)
IN8bio to Present at May Investor and Scientific Conferences

NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and...

INAB : 1.0200 (-1.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

IN8bio Inc. is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company's principal candidate includes INB-200, which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 1.1300
2nd Resistance Point 1.1000
1st Resistance Point 1.0600
Last Price 1.0200
1st Support Level 0.9900
2nd Support Level 0.9600
3rd Support Level 0.9200

See More

52-Week High 3.4800
Fibonacci 61.8% 2.3989
Fibonacci 50% 2.0650
Fibonacci 38.2% 1.7311
Last Price 1.0200
52-Week Low 0.6500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar